SYSTEMIC SCLEROSIS (SSC)

This early-stage study tests a new medicine called GB261 in 10 people with systemic sclerosis, a disease that causes skin thickening and organ damage. The main goal is to check safety and how the body handles the drug. Participants must have moderate to severe skin involvement an…

This early-phase study tests a new drug, cizutamig, in 10 adults with systemic sclerosis, a condition that causes skin hardening and organ damage. The main goal is to check if the drug is safe and tolerable. Researchers will also look at how the body processes the drug and whethe…

This early-stage trial tests a new stem cell treatment (HS_SW01) for people with systemic sclerosis, a disease that causes skin hardening and organ damage. The main goal is to see if the treatment is safe and tolerable in 21 adults aged 18-65. Researchers will also check if it im…

This early study tests a new treatment called HN2302 in 12 adults with autoimmune diseases like lupus or scleroderma. The main goal is to check if it is safe and to see how the body makes special immune cells to fight the disease. It is a first step to find out if this approach c…

This early-stage study tests a new treatment called BEN301 for people with autoimmune diseases like scleroderma, rheumatoid arthritis, Sjogren's syndrome, and inflammatory muscle diseases. The therapy uses specially engineered immune cells (CAR-Tregs) to calm the overactive immun…

This study looks at a blood protein called FAP, which is linked to tissue scarring and inflammation. Researchers will measure FAP levels in 111 adults with rheumatoid arthritis or systemic sclerosis, plus healthy volunteers, and compare them with standard exams, imaging, and lung…